Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.61 |
| ▸ | LCK | P06239 | 10/20 | 0.55 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.55 |
| ▸ | SCD | O00767 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL211650 | 0.92 | HDAC1 (0.60) | HDAC1LCKSCD | |
| SCHEMBL210651 | 0.91 | HDAC1 (0.64) | HDAC1LCKSCDNPC1RAB9A | |
| SCHEMBL211848 | 0.88 | HDAC1 (0.56) | HDAC1LCKSCDNPC1RAB9A | |
| SCHEMBL212264 | 0.87 | HDAC1 (0.61) | HDAC1LCKSCDSMN1; SMN2TP53 | |
| SCHEMBL2733518 | 0.87 | HDAC1 (0.58) | HDAC1LCKSCDCSNK1D | |
| SCHEMBL210833 | 0.85 | AURKB (0.60) | HDAC1LCKSCDSMN1; SMN2TP53 | |
| SCHEMBL2733826 | 0.85 | HDAC1 (0.79) | HDAC1MAP3K5 | |
| SCHEMBL209892 | 0.82 | HDAC1 (0.68) | HDAC1 | |
| SCHEMBL5584436 | 0.81 | KMT2A (0.51) | HDAC1NPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL210488 | 0.80 | HDAC1 (0.64) | HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885LCK 1674/4885MAP3K5 979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.